GeoVax Labs (GOVX) Change in Accured Expenses (2010 - 2025)
GeoVax Labs (GOVX) posted quarterly Change in Accured Expenses of -$182441.0 for Q4 2025, down 136.55% year-over-year from $499160.0 in Q4 2024, and up 74.12% quarter-over-quarter from -$705047.0 in Q3 2025.
GeoVax Labs (GOVX) Change in Accured Expenses (2010 - 2025) Analysis & Trends
GeoVax Labs (GOVX) has reported Change in Accured Expenses for 16 consecutive years, with -$182441.0 the latest figure, recorded in Q4 2025.
- In Q4 2025, Change in Accured Expenses fell 136.55% year-over-year to -$182441.0; the TTM figure through Dec 2025 stood at -$1.5 million (down 255.25% YoY), while the FY2025 annual figure was -$1.5 million, down 255.25% from the prior year.
- Change in Accured Expenses grew to -$182441.0 in Q4 2025 per GOVX's latest filing, from -$705047.0 in the prior quarter.
- Across five years, Change in Accured Expenses topped out at $7.1 million in Q4 2021 and bottomed at -$3.7 million in Q3 2024.
- Historically, Change in Accured Expenses has averaged $50830.4 across 5 years, with a median of -$195640.0 in 2023.
- Annual changes were most pronounced in 2021 — Change in Accured Expenses jumped 6323.45% — and 2022, when it tumbled 440.48%.
- GeoVax Labs' Change in Accured Expenses stood at $7.1 million in 2021, then plunged by 128.75% to -$2.0 million in 2022, then sank by 74.47% to -$3.6 million in 2023, then jumped by 114.01% to $499160.0 in 2024, then tumbled by 136.55% to -$182441.0 in 2025.
- Business Quant data shows GOVX's Change in Accured Expenses at -$182441.0 in Q4 2025, -$705047.0 in Q3 2025, and -$406110.0 in Q2 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Change in Accured Expenses (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | 222.50 Mn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | 492.70 Mn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | - |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | 11.00 Mn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | 212.44 Mn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | 61.62 Mn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | - |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | 68.82 Mn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | - |
| 10 | GeoVax Labs | 2.88 Mn | -260,493.75 | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | -182,441.00 |
| Dec 31, 2025 | -182,441.00 |
| Sep 30, 2025 | -705,047.00 |
| Sep 30, 2025 | -705,047.00 |
| Jun 30, 2025 | -406,110.00 |
| Jun 30, 2025 | -406,110.00 |
| Mar 31, 2025 | -171,998.00 |
| Mar 31, 2025 | -171,998.00 |
| Dec 31, 2024 | 499,160.00 |
| Dec 31, 2024 | 499,160.00 |
| Sep 30, 2024 | -3.66 Mn |
| Sep 30, 2024 | -3.66 Mn |
| Jun 30, 2024 | 2.96 Mn |
| Jun 30, 2024 | 2.96 Mn |
| Mar 31, 2024 | -215,974.00 |
| Mar 31, 2024 | -215,974.00 |
| Dec 31, 2023 | -3.56 Mn |
| Dec 31, 2023 | -3.56 Mn |
| Sep 30, 2023 | 3.00 Mn |
| Sep 30, 2023 | 3.00 Mn |